Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective over the last decade to enable the oral delivery of peptide-based therapeutics as well as other molecules with low oral bioavailability. Enteris BioPharma’s internal clinical product pipeline consists of Ovarest® (oral leuprolide tablet), currently being evaluated in for endometriosis, and Tobrate™ (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products approximate $1 billion in aggregate. Additionally, Enteris BioPharma’s oral peptide delivery technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA™, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.